{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:18:16Z","timestamp":1792001896997,"version":"4.4.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"vor","delay-in-days":365,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.jtho.2016.04.013","type":"journal-article","created":{"date-parts":[[2016,4,30]],"date-time":"2016-04-30T14:44:19Z","timestamp":1462027459000},"page":"1345-1356","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors"],"prefix":"10.1016","volume":"11","author":[{"given":"Anna Teresa","family":"Alberobello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yisong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frans Joseph","family":"Beerkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Conforti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine N.","family":"McCutcheon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanhua","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Raffeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raneen","family":"Rahhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Wen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Giaccone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2016.04.013_bib1","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.lungcan.2012.11.015","article-title":"Reproducibility of the WHO classification of thymomas: practical implications","volume":"79","author":"Zucali","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2016.04.013_bib2","doi-asserted-by":"crossref","first-page":"S286","DOI":"10.1097\/JTO.0b013e3181f209a8","article-title":"Thymoma and thymic carcinoma: molecular pathology and targeted therapy","volume":"5","author":"Strobel","year":"2010","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2016.04.013_bib3","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1200\/JCO.2011.36.0487","article-title":"Thymic malignancies: from clinical management to targeted therapies","volume":"29","author":"Kelly","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2016.04.013_bib4","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/cncr.10226","article-title":"The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients","volume":"94","author":"Okumura","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2016.04.013_bib5","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ijrobp.2003.11.021","article-title":"Thymic carcinoma: state of the art review","volume":"59","author":"Eng","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtho.2016.04.013_bib6","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.lungcan.2012.08.002","article-title":"Molecular aspects of thymic carcinoma","volume":"78","author":"Weissferdt","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2016.04.013_bib7","doi-asserted-by":"crossref","first-page":"e367","DOI":"10.14694\/EdBook_AM.2014.34.e367","article-title":"Systemic treatment of advanced thymic malignancies","author":"Kelly","year":"2014","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.jtho.2016.04.013_bib8","doi-asserted-by":"crossref","first-page":"5392","DOI":"10.1158\/1078-0432.CCR-14-0968","article-title":"A\u00a0phase I\/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study","volume":"20","author":"Thomas","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2016.04.013_bib9","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/JTO.0b013e318284378f","article-title":"\u201cPseudocavitation\u201d in thymic carcinoma during treatment with sunitinib","volume":"8","author":"Tiseo","year":"2013","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2016.04.013_bib10","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/sj.bjc.6605740","article-title":"Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience","volume":"103","author":"Strobel","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2016.04.013_bib11","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1470-2045(13)70596-5","article-title":"Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial","volume":"15","author":"Rajan","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2016.04.013_bib12","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.1994.12.6.1164","article-title":"Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group","volume":"12","author":"Loehrer","year":"1994","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2016.04.013_bib13","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.thorsurg.2010.08.003","article-title":"Chemotherapy for thymic tumors: induction, consolidation, palliation","volume":"21","author":"Rajan","year":"2011","journal-title":"Thorac Surg Clin"},{"key":"10.1016\/j.jtho.2016.04.013_bib14","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00109-014-1165-y","article-title":"Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer","volume":"92","author":"Gower","year":"2014","journal-title":"J\u00a0Mol Med (Berl)"},{"key":"10.1016\/j.jtho.2016.04.013_bib15","doi-asserted-by":"crossref","first-page":"S361","DOI":"10.1097\/JTO.0b013e3181f21114","article-title":"Targeted therapy for advanced thymic tumors","volume":"5","author":"Rajan","year":"2010","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2016.04.013_bib16","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1158\/1078-0432.CCR-09-0644","article-title":"Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas","volume":"15","author":"Girard","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2016.04.013_bib17","doi-asserted-by":"crossref","first-page":"e42669","DOI":"10.1371\/journal.pone.0042669","article-title":"Molecular analysis of thymoma","volume":"7","author":"Badve","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2016.04.013_bib18","doi-asserted-by":"crossref","first-page":"e351","DOI":"10.1038\/cddis.2012.92","article-title":"Copy number aberrations of BCL2 and CDKN2A\/B identified by array-CGH\u00a0in thymic epithelial tumors","volume":"3","author":"Petrini","year":"2012","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jtho.2016.04.013_bib19","doi-asserted-by":"crossref","first-page":"577","DOI":"10.6004\/jnccn.2013.0073","article-title":"Thymoma versus thymic carcinoma: differences in biology impacting treatment","volume":"11","author":"Kelly","year":"2013","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.jtho.2016.04.013_bib20","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1038\/oncsis.2014.25","article-title":"ASXL1 and DNMT3A mutation in a cytogenetically normal B3 thymoma","volume":"3","author":"Belani","year":"2014","journal-title":"Oncogenesis"},{"key":"10.1016\/j.jtho.2016.04.013_bib21","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s11748-014-0437-3","article-title":"Cyclin-dependent kinase inhibitors, p16 and p27, demonstrate different expression patterns in thymoma and thymic carcinoma","volume":"62","author":"Omatsu","year":"2014","journal-title":"Gen Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtho.2016.04.013_bib22","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/ng.3016","article-title":"A\u00a0specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors","volume":"46","author":"Petrini","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2016.04.013_bib23","doi-asserted-by":"crossref","first-page":"7336","DOI":"10.1038\/srep07336","article-title":"Mutations of epigenetic regulatory genes are common in thymic carcinomas","volume":"4","author":"Wang","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtho.2016.04.013_bib24","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/ijc.2910500216","article-title":"Establishment and characterization of a thymic carcinoma cell line (Ty-82) carrying t(15;19)(q15;p13) chromosome abnormality","volume":"50","author":"Kuzume","year":"1992","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jtho.2016.04.013_bib25","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/BF01541736","article-title":"Characterization of human thymic epithelial cell surface antigens: phenotypic similarity of thymic epithelial cells to epidermal keratinocytes","volume":"15","author":"Patel","year":"1995","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jtho.2016.04.013_bib26","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1111\/j.1349-7006.2008.00897.x","article-title":"Multiple inflammatory cytokine-productive ThyL-6 cell line established from a patient with thymic carcinoma","volume":"99","author":"Inai","year":"2008","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jtho.2016.04.013_bib27","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/labinvest.2012.115","article-title":"Establishment and characterization of a novel cell line derived from human thymoma AB tumor","volume":"92","author":"Gokmen-Polar","year":"2012","journal-title":"Lab Invest"},{"key":"10.1016\/j.jtho.2016.04.013_bib28","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/1759-7714.12163","article-title":"Establishment and characterization of a novel cell line derived from thymoma with myasthenia gravis patients","volume":"6","author":"Wang","year":"2015","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.jtho.2016.04.013_bib29","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1002\/ijc.23335","article-title":"Establishment, characterization and drug sensitivity testing in primary cultures of human thymoma and thymic carcinoma","volume":"122","author":"Ehemann","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jtho.2016.04.013_bib30","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0955-0674(99)80029-5","article-title":"Signalling through phosphoinositide 3-kinases: the lipids take centre stage","volume":"11","author":"Leevers","year":"1999","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.jtho.2016.04.013_bib31","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/01.cco.0000198021.99347.b9","article-title":"Oncogenic PI3K and its role in cancer","volume":"18","author":"Samuels","year":"2006","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.jtho.2016.04.013_bib32","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/JTO.0000000000000397","article-title":"Massively parallel sequencing identifies recurrent mutations in TP53 in thymic carcinoma associated with poor prognosis","volume":"10","author":"Moreira","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2016.04.013_bib33","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1158\/2159-8290.CD-12-0280","article-title":"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability","volume":"2","author":"Cheung","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2016.04.013_bib34","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1158\/2159-8290.CD-13-0103","article-title":"Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers","volume":"3","author":"Lui","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2016.04.013_bib35","doi-asserted-by":"crossref","first-page":"7336","DOI":"10.1038\/srep07336","article-title":"Mutations of epigenetic regulatory genes are common in thymic carcinomas","volume":"4","author":"Wang","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtho.2016.04.013_bib36","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1158\/2159-8290.CD-11-0039","article-title":"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability","volume":"1","author":"Cheung","year":"2011","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2016.04.013_bib37","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/ng.2331","article-title":"De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes","volume":"44","author":"Riviere","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2016.04.013_bib38","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/jamaoto.2015.0471","article-title":"Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies","volume":"41","author":"Wirtz","year":"2015","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.jtho.2016.04.013_bib39","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2002165","article-title":"Structural basis for activation and inhibition of class I phosphoinositide 3-kinases","volume":"4","author":"Vadas","year":"2011","journal-title":"Sci Signal"},{"key":"10.1016\/j.jtho.2016.04.013_bib40","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1158\/1535-7163.MCT-08-1200","article-title":"Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941","volume":"8","author":"Raynaud","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jtho.2016.04.013_bib41","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1158\/1078-0432.CCR-15-2276","article-title":"Strategically timing inhibition of phosphatidylinositol 3-kinase to maximize therapeutic index in estrogen receptor alpha-positive, PIK3CA-mutant breast cancer","volume":"22","author":"Yang","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2016.04.013_bib42","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1158\/1078-0432.CCR-11-2088","article-title":"GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in\u00a0vitro and in\u00a0vivo","volume":"18","author":"Wallin","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2016.04.013_bib43","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1158\/1078-0432.CCR-12-2853","article-title":"A\u00a0potent combination of the novel PI3K inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal","volume":"19","author":"Floris","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2016.04.013_bib44","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/onc.2012.594","article-title":"The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma","volume":"33","author":"Munugalavadla","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.jtho.2016.04.013_bib45","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/ijc.29378","article-title":"Antibody targeting of HER2\/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer","volume":"137","author":"Poovassery","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jtho.2016.04.013_bib46","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1158\/1078-0432.CCR-14-0947","article-title":"First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors","volume":"21","author":"Sarker","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2016.04.013_bib47","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.celrep.2013.12.035","article-title":"Assessing PIK3CA and PTEN in early-phase trials with PI3K\/AKT\/mTOR inhibitors","volume":"6","author":"Janku","year":"2014","journal-title":"Cell Rep"},{"key":"10.1016\/j.jtho.2016.04.013_bib48","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S1470-2045(10)70130-3","article-title":"Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis","volume":"11","author":"De Roock","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2016.04.013_bib49","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1172\/JCI37539","article-title":"Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus","volume":"120","author":"Di Nicolantonio","year":"2010","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jtho.2016.04.013_bib50","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/nm.1890","article-title":"Effective use of PI3K\u00a0and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers","volume":"14","author":"Engelman","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.jtho.2016.04.013_bib51","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1158\/0008-5472.CAN-07-6656","article-title":"Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance","volume":"69","author":"Ihle","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2016.04.013_bib52","doi-asserted-by":"crossref","first-page":"e22769","DOI":"10.1371\/journal.pone.0022769","article-title":"PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers","volume":"6","author":"Janku","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2016.04.013_bib53","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1200\/JCO.2011.36.1196","article-title":"PI3K\/AKT\/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations","volume":"30","author":"Janku","year":"2012","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086416303392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086416303392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T17:23:58Z","timestamp":1536773038000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086416303392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":53,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S1556086416303392"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2016.04.013","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2016.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}